FATE Q2 2022 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+38.3% YoY

Gross Profit

-$63M-338.3% margin

Operating Income

-$83M-448.1% margin

Net Income

-$76M-410.3% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$63M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$807M

Total Liabilities

$227M

Stockholders' Equity

$580M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$13M	+38.3%
Gross Profit	-$63M	-$35M	-81.3%
Operating Income	-$83M	-$47M	-77.7%
Net Income	-$76M	-$55M	-38.0%

Revenue Segments

Upfront Fee And Equity Premium

$7M100%